List view / Grid view

Dr Vasant Narasimhan

 

news

Novartis plans head-to-head studies of Cosentyx versus Humira

Long-term analyses suggest Cosentyx may lead to higher responses than…

8 June 2016 | By Victoria White, Digital Content Producer

Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...

news

Cosentyx superior to Stelara in achieving sustained skin clearance in psoriasis

New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that…

7 March 2016 | By

New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.